%0 Journal Article
%9 ACL : Articles dans des revues avec comité de lecture non répertoriées par l'AERES
%A Plantier, J.C.
%A Damond, F.
%A Lasky, Mariama
%A Sankalé, J.L.
%A Apetrei, C.
%A Peeters, Martine
%A Buzelay, L.
%A M'Boup, S.
%A Kanki, P.
%A Delaporte, Eric
%A Simon, F.
%A Barin, F.
%T V3 serotyping of HIV-1 infection : correlation with genotyping and limitations
%D 1999
%L fdi:010018170
%G ENG
%J Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
%@ 1077-9450
%K SIDA ; VIRUS ; TYPOLOGIE ; ANTICORPS ; CLASSIFICATION ; SEROLOGIE ; TEST ; IMMUNOLOGIE ; GENOTYPE
%K SEROTYPAGE ; PEPTIDE V3
%N 5
%P 432-441
%U https://www.documentation.ird.fr/hor/fdi:010018170
%> https://horizon.documentation.ird.fr/exl-doc/pleins_textes/pleins_textes_6/b_fdi_49-50/010018170.pdf
%V 20
%W Horizon (IRD)
%X HIV-1 V3 serotyping is a classification of immunodeficiency viruses based on antibody binding to V3 peptides that allows obtaining information on circulating subtypes that could be important for population-based epidemiologic studies. Recently, several laboratories have developed V3 enzyme-immunoassays (EIAs) using V3 peptides of subtypes A to E. In the present study, the utility of including additional peptides of subtypes F to H to the EIA was evaluated on a panel of 203 well-characterized serum samples from patents with diverse geographic origins (22 countires) and known HIV-1 genotype (79 A, 61 B, 21 C, 7 D, 7 E, 21 F, 6 G, 1 H). The results indicate a high predictive value (ppv) for serotypes B (greater than or equal to 0.86), D (1) and E (0.88), and confirm the difficulty of predicting genotype A or C based on serotype A or C. Results also indicate that inclusion of the F peptide in the V3 EIAs may be useful (ppv = 0.61), but introduction of peptides G and H failed to demonstrate significant sensitivity or specificity for these subtypes. Correlation between serotyping and amino-acid sequences of the V3 region from 103 samples allowed the identification of key amino-acids that appear essential for subtype-specific seroreactivity. (Résumé d'auteur)
%$ 052MALTRA03